AHA Scientific Sessions 2022 Late-Breaking Science Coverage
Published: 02 November 2022
-
Views:
5389 -
Likes:
7
-
Views:
5389 -
Likes:
7
-
8m 12s
-
5m 39sPart 3 | Session 2 EAST-AFNET4: Rhythm Control Therapy in Atrial Fibrillation
-
7m 23sPart 3 | Session 3 BT001 PIVOTAL: nCBT in Pts with Type II Diabetes
-
8m 38sPart 3 | Session 4 PRECISION: Aprocitentan in the Treatment of Resistant Hypertension
-
9m 16s
-
5m
-
10m 6sPart 3 | Session 7 SPYRAL HTN-ON MED: Renal Denervation in Patients with Hypertension
-
14m 20sPart 4 | Session 1 The PROMINENT Trial With Dr Kaur & Dr Pradhan
-
14m 28sPart 4 | Session 2 The OCEAN(a)-DOSE Trial With Dr Gurleen Kaur & Dr Michelle L O'Donoghue
-
18m 1sPart 4 | Session 3 The EMPA-Kidney Trial With Dr Wilcox & Dr Preiss
-
15m 37sPart 4 | Session 4 The PREVENT-HD Randomized Clinical Trial With Dr Fadah & Dr Piazza
-
14m 14sPart 4 | Session 5 The RESPECT EPA Trial With Prof Daida & Dr Jumkhawala
-
13m 6sPart 4 | Session 6 The PROGRESSIVE-AF Trial With Dr Wilcox & Dr Andrade
-
13m 45sPart 4 | Session 7 The ECMO-CS Trial With Dr Ostadal & Dr Jumkhawala
-
18m 58sPart 4 | Session 8 The IRONMAN Trial With Dr Amir & Dr Kalra
-
2m 9sPart 5 | Session 1 Being a Researcher With Investigator, Dr Julian Gillmore
-
56sPart 5 | Session 2 Research in 2022 With Investigator, Dr Shino Kany
-
3m 1sPart 5 | Session 3 Making a Difference With Physician-Scientist, Dr Schlaich
-
2m 51sPart 5 | Session 4 What Makes Dr Bonaca excited about CV Science in 2022?
-
5m 44sPart 6 | Session 1 Late-breaking Science Highlights With Dr Joseph A Hill
-
12m 38sPart 6 | Session 2 4 Trials That Will Change Your Practice With Interventionalist, Dr Alasnag
-
35m 25sPart 1 | Session 1 What's Hot at AHA22? Late-Breaking Science Wrap-up Nicolas M Van Mieghem, Joost Daemen
-
15m 30sPart 1 | Session 2 What's Hot at AHA22? Late-Breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
13m 29sPart 2 | Session 1 The TRANSFORM-HF Trial WIth Dr Van Spall & Dr Mentz Robert Mentz, Harriette Van Spall
-
21m 14sPart 2 | Session 2 The STRONG-HF Trial With Dr Van Spall & Prof Mebazaa Alexandre Mebazaa, Harriette Van Spall
Overview
Stay updated with the latest data in cardiovascular science with the help of recognised experts and new voices offering practical summaries, in-depth discussions and critical reviews.
With their fingers on the pulse of cardiovascular innovation, Prof Van Mieghem and Dr Daemen offer their succinct and insightful take on the most expected trials of AHA 22 in their regular review series View from the Thoraxcenter.
Dr Harriette Van Spall, recipient of this year’s AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they talk about methodology, results, and impact on patient care.
This year we partner with @CardioNerds to bring the fresh perspective of a great team founded to democratize cardiovascular education. Get the most of the new data from an interview series featuring principal investigators and trainees from the CardioNerds family.
Look behind the scientific achievement and learn more about the personal motivations of some of the investigators, benefit from their advice for early career researchers through our Behind the Heart series.
More from this programme
Part 1
View from the Thoraxcenter: Review Series
Part 2
Late-breaker Discussions With Harriette Van Spall
Part 3
Expert Interviews
Part 4
Radcliffe & CardioNerds @AHA22
Part 5
Behind the Heart
Part 6
AHA22 Highlights
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…